Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care

Canadian Family Physician

Volumn 57, Issue 2, 2011, Pages 184-189

  Pallan, Shelley ^a   Khan, Aliya ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIFEDIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; RALOXIFENE; BISPHOSPHONIC ACID DERIVATIVE;

ASYMPTOMATIC DISEASE; BONE DENSITY; CALCIUM BLOOD LEVEL; COGNITIVE DEFECT; FAMILIAL DISEASE; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FAMILY MEDICINE; FATIGUE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; MEDLINE; MOOD DISORDER; PARATHYROIDECTOMY; PATIENT MONITORING; PATIENT SELECTION; PRIMARY HYPERPARATHYROIDISM; PRIMARY MEDICAL CARE; REVIEW; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; BLOOD; PRIMARY HEALTH CARE;

CALCIUM; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; PARATHYROIDECTOMY; PRIMARY HEALTH CARE;

EID: 79952087103     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Khan AA, Bilezikian JP, Potts JT Jr; Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab 2009;94(2):333-4.
2. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81(6):2036-40. (Pubitemid 26175923)
3. Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163(2):184-7. (Pubitemid 30625659)
4. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132(3):359-72.
5. Souza ER, Scrignoli JA, Bezerra FC, Ribeiro SL, Passos LF. Devastating skeletal effects of delayed diagnosis of complicated primary hyperparathyroidism because of ectopic adenoma. J Clin Rheumatol 2008;14(5):281-4.
6. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, Hanley DA, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94(2):340-50.
7. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42(1):35-70. (Pubitemid 41656709)
8. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004;89(11):5583-91. (Pubitemid 39518444)
9. Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996;81(12):4204-11. (Pubitemid 26412018)
10. Wermers RA, Kearns AE, Jenkins GD, Melton LJ 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med 2007;120(10):911. e9-15. Epub 2007 Apr 16.
11. Haden ST, Stoll AT, McCormick S, Scott J, Fuleihan G el-H. Alterations in parathyroid hormone dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997;82(9):2844-8. (Pubitemid 27385637)
12. Beard CM, Heath H 3rd, O'Fallon WM, Anderson JA, Earle JD, Melton LJ 3rd. Therapeutic radiation and hyperparathyroidism. A case-control study in Rochester, Minn. Arch Intern Med. 1989;149(8):1887-90. (Pubitemid 19200850)
13. Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 1995;80(1):254-7.
14. Mishra SK, Agarwal G, Kar DK, Gupta SK, Mithal A, Rastad J. Unique clinical characteristics of primary hyperparathyroidism in India. Br J Surg 2001;88(5):708-14. (Pubitemid 34014642)
15. Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician 2003;67(9):1959-66. (Pubitemid 36554449)
16. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004;89(11):5415-22. (Pubitemid 39518419)
17. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92(5):1687-92. Epub 2007 Feb 6. (Pubitemid 46997172)
18. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007;92(8):3114-21. Epub 2007 May 29. (Pubitemid 47236379)
19. Helliwell M. Rheumatic symptoms in primary hyperparathyroidism. Postgrad Med J 1983;59(690):236-40. (Pubitemid 13117224)
20. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94(2):351-65.
21. Jebasingh F, Jacob JJ, Shah A, Paul TV, Seshadri MS. Bilateral maxillary brown tumours as the first presentation of primary hyperparathyroidism. Oral Maxillofac Surg 2008;12(2):97-100.
22. Erem C, Hacihasanoglu A, Cinel A, Ersöz HO, Reis A, Sari A, et al. Sphenoid sinus brown tumour, a mass lesion of occipital bone and hypercalcemia: an unusual presentation of primary hyperparathyroidism. J Endocrinol Invest 2004;27(4):366-9. (Pubitemid 38744617)
23. Fouda MA. Primary hyperparathyroidism: King Khalid University Hospital experience. Ann Saudi Med 1999;19(2):110-5. (Pubitemid 29355582)
24. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92(8):3001-5. Epub 2007 May 29. (Pubitemid 47236362)
25. Lundgren E, Hagström EG, Lundin J, Winnerbäck K, Roos J, Ljunghall S, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002;26(8):931-6. Epub 2002 June 6.
26. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63(5):506-13.
27. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002;17(Suppl 2):N75-80.
28. Consensus Development Task Force on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism. Asymptomatic primary hyperparathyroidism: standards and guidelines for diagnosis and management in Canada. Endocr Pract 2003;9(5):400-5.
29. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94(2):335-9.
30. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93(9):3462-70. Epub 2008 Jun 10.
31. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94(2):366-72.
32. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001;16(1):113-9. (Pubitemid 32046195)
33. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88(2):581-7. (Pubitemid 36207794)
34. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89(7):3319-25. (Pubitemid 38951898)
35. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 1996;125(5):360-8. (Pubitemid 126449705)
36. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94(2):373-81.
37. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88(3):1174-8. (Pubitemid 36337773)